cyrilzakka/clinical-trials huggingface dataset:
Laser Versus Cryotherapy for the Treatment of Recalcitrant Warts

To evaluate whether laser was superior to cryotherapy for recalcitrant warts

Patients with recalcitrant warts were randomized equally to receive laser or cryotherapy every 3 to 4 weeks, for a maximum of 4 sessions.The primary outcomes were the cure rate at 16 weeks; secondary outcomes included time to clearance of warts, patient satisfaction with the treatment and treatment-related adverse effects.

Eligibility Criteria:
Inclusion Criteria:

* Patients with HPV2/27/57-induced recalcitrant warts, including periungualor mosaic warts, common or plantar warts with a duration of longer than 1 year, and common or plantar warts previously received no more than two sessions of cryotherapy
* Total number of warts is ≤10 .
* Aged 18 years or older.

Exclusion Criteria:

* Patients are currently participating in another trial for the treatment of cutaneous warts.
* Patients have taken immunosuppressant drugs (such as oral corticosteroids) during the past three months.
* Patients have impaired healing eg due to diabetes, vitamin A deficiency, hyperthyroidism and hypothyroidism.
* Patients have autoimmune diseases (such as systemic lupus erythematosus, dermatomyositis, scleroderma or other diseases).
* Patients are pregnant or ready for pregnancies or breast-feeding.
* Patients have cold intolerance (such as cold urticaria, cryoglobulinaemia, cold agglutinin syndrome or Raynaud's syndrome).
* Patients have local pain intolerance.
* Patients have local hypoesthesia.
* Patients are unable to tolerate laser or cryotherapy.
Transdermal Basal Insulin Patch Study in Type 1 Diabetes

This study is designed to evaluate the pharmacokinetics/pharmacodynamics of an investigational basal insulin patch in type 1 diabetes patients.

The study is looking for patients that meet the following criteria:

* Duration of type diabetes greater than or equal to 10 years
* HbA1C less than or equal to 9.0%
* C-peptide negative
* Ages 18 - 65, male or female
* Body Mass Index (BMI) 18.5 - 32
* Non-smoker
* No advanced diabetes complications
* Not pregnant or breast feeding

Eligibility Criteria:
Inclusion Criteria:

* Duration of type 1 diabetes greater than or equal to 10 years
* HbA1c less than or equal to 9.0%
* C-peptide negative
* Ages 18 - 65, male or female
* BMI 18.5 - 32
* Non- smoker
* No advance diabetes complications
* Not pregnant or breast feeding

Exclusion Criteria:

* Arm or leg rashes, open wounds, or skin conditions
* Psychiatric disorders
* Participation in a clinical research trial in last 3 months
* Clinically significant acute illness
Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis

Plaque Psoriasis is a chronic inflammatory disease in which skin cells build up and develop scaly red and white patches on the skin. Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by an overactive immune system where the body attacks healthy tissue by mistake. This study will evaluate how safe risankizumab is for the treatment of plaque psoriasis or psoriatic arthritis and to assess change in disease symptoms.

Risankizumab is an approved drug for the treatment of psoriasis and psoriatic arthritis. Around 3000 adult participants with a moderate to severe plaque psoriasis or psoriatic arthritis who had been prescribed risankizumab by their doctor will be enrolled in this study in multiple sites across Korea. The sample size for this study is a requirement by local authorities.

Participants will receive risankizumab prefilled syringe for injection for 52 weeks as prescribed by their physician.

There is expected to be no additional burden for participants in this study. All study visits will occur during routine clinical practice and participants will be followed for 52 weeks.


Eligibility Criteria:
Inclusion Criteria:

* Suitable for the treatment with risankizumab according to the approved local label.
* Voluntarily agree to participate in this study and sign informed consent.

Exclusion Criteria:

- Contraindications to risankizumab as listed on the approved local label.
Genicular Artery Embolization (GAE) for the Treatment of Chronic Post Knee Arthroplasty Pain

This study seeks to evaluate the safety and efficacy of genicular artery embolization (GAE) as a treatment for patients with chronic pain following primary total knee arthroplasty (TKA) or revision TKA at 6 months as measured by the Knee Injury and Osteoarthritis Outcome Score (KOOS).

This is a single center, single arm, prospective pilot study evaluating the safety and efficacy of genicular artery embolization (GAE) for treatment of chronic pain following primary total knee arthroplasty (TKA) or revision TKA. Following screening, eligible participants will be offered enrollment. Patients who demonstrate baseline imaging findings of knee synovitis either on US, MRI, or both modalities will be offered GAE. Genicular artery embolization will be performed using a SeQure® microcatheter (Guerbet LLC, Villepinte, France) using Embozene microspheres (Varian Medical Systems, Palo Alto, CA).

Eligibility Criteria:
Inclusion Criteria:

1. Ambulatory
2. History of total knee arthroplasty or revision arthroplasty in the symptomatic knee
3. Moderate to severe knee pain: pain VAS ≥50 mm
4. Knee pain resistant to at least 3 months of conservative therapy including pharmacologic therapy or intra-articular injection.
5. Absence of pregnancy at time of screening as determined by urine HCG
6. Provision of signed and dated informed consent form
7. Willing, able, and mentally competent to provide informed consent and to tolerate angiography, US, and MRI.

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. History of severe peripheral arterial disease symptoms including claudication, diminished or absent lower extremity pulses, leg numbness or weakness or known arterial atherosclerosis or occlusion that would limit selective angiography
2. History of inflammatory arthropathy such as rheumatoid arthritis, spondyloarthropathies, crystal disease, gout, pseudogout, or lupus
3. Presence of non-MRI compatible devices (e.g., cardiac pacemaker).
4. Known history of anaphylaxis to iodinated or gadolinium-based contrast agents
5. BMI greater than 50
6. Renal dysfunction as defined by serum creatinine \>1.6 dl/mg or eGFR \<60 obtained within 30 days of procedure.
7. Uncorrectable coagulopathy (platelet count \< 50,000, international normalized ratio \>1.5 within 30 days of procedure
8. Active systemic or local knee infection
9. Pregnant or intent to become pregnant during the study
Prediction of Fluid Responsiveness From Passive Leg Raising Induced Changes in Perfusion Index and Pleth Variability Index

The aim of the study is to evaluate whether changes in Perfusion Index (PI) and Pleth Variability Index (PVI) during passive leg raising test can predict fluid responsiveness in spontaneously breathing patients.

Fluid responsive patients are defined as showing an increase in cardiac output \>10% during a passive leg raising test, measured semi-invaseively with FloTrac® (Edwards LifeSciences. Irvine, United States).


Eligibility Criteria:
Inclusion Criteria:

* Adult patients admitted to the intensive or intermediate care unit after abdominal surgery (including urological and gynecological surgery performed in laparotomy)
* Spontaneous breathing
* Arterial line already in place
* Oral and written informed consent obtained

Exclusion Criteria:

* Age \<18 years
* Abdominal trauma as the reason for surgery
* Missing informed consent
Effect of Sarcopenia in Stroke Patients

Primary research purpose:

-Prospective study to screen post stroke patients with sarcopenia and evaluate its effect on recovery

Secondary research purpose:

* To determine the degree of sarcopenia and correlation with poor functional prognosis of stroke in the stroke patient group.
* To determine the degree of sarcopenia and correlation with dixon MRI of thigh muscle
* To evaluate surface EMG (SEMG)-based signals and correlation with sarcopenia
* To determine the degree of sarcopenia and correlation with brain morphometric changes

Patients with first-ever stroke will be enrolled and assessed for sarcopenia. The evaluation parameters will include standard sarcopenia parameters and also SEMG-based signals and imaging studies.

Eligibility Criteria:
Inclusion Criteria:

* Patients 65 years of age or older, stroke patients with first onset within 4 weeks

Exclusion Criteria:

* Patients who have not been evaluated for sarcopenia
* Patients with neuromuscular diseases other than stroke that may affect gait function
* Patients unable to conduct clinical trials according to instructions
* Patients with uncontrolled medical/surgical disease
* Patients with metal substances in the body such as cardiac pacemakers, cochlear implants, etc.
* Patients who have difficulty collecting blood
* Patients who are difficult to follow up after 6 months of onset due to moving to another area
* Patients who have Parkinson's disease, dementia, or have a history of neuromuscular diseases such as Guillain-Barré syndrome or myasthenia gravis
A New Prediction Mode for Predicting the Risk of Pressure Injury in Patients Undergoing Liver Transplantation

Pediatric population is at a high-risk of pressure injury (PI). Patients undergoing liver transplantation are more prone to PIs compared with other types of surgery. However, there is a lack of sensitive and specific assessment tools for the risk of PI in patients undergoing liver transplantation. How to accurately predict the incidence of PI in patients undergoing liver transplantation is needs to be urgently eliminated. The study is conducted in the Renji Hospital, School of Medicine, Shanghai Jiaotong University which is the largest liver transplantation center in China.

Data of 1200 eligible patients undergoing liver transplantation between July 2018 and June 2021 are selected.The sample size was randomly divided into 70% discovery set and 30% validation set according to 7:3. 70% of the discovery dataset are used for the establishment of risk prediction model. The univariate analysis is used to evaluate PI-associated risk factors. In addition, a multivariate logistic regression model is developed using selected variables and P\<0.05 in the univariate analysis is used to identify independent risk factors for PIs. The odds ratio for each independent variable is determined with a 95% confidence interval. Finally, a nomogram of predictive model is generated on the basis of the results of multivariate analysis.Discrimination capability, calibration degree, and clinical value will be used to verify the efficacy of the prediction model. This study develops and validates a prediction model for predicting the risk of PI in patients undergoing liver transplantation. Using this prediction model, we will develop decision-support systems to prevent PI in the future.

Eligibility Criteria:
Inclusion Criteria:

* undergoing liver transplantation surgery (i.e., living-donor liver transplantation and deceased donor liver transplantation)
* patients undergoing the first surgery during their hospitalization

Exclusion Criteria:

* a history of PI before undergoing surgery
* patients with skin disease that could affect observation of skin and the outcome
* patients who died during surgery
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.

Anemia is a common health problem. Depending on a geographical region, anemia affects even 50% of population. Among patients admitted to the intensive care unit (ICU) anemia may affect as much as 66% of patients. Moreover, many patients develop anemia during the ICU stay. In general population the most common cause of anemia is iron deficiency (ID). The investigators lack information on the incidence of ID and anemia of inflammation (AI) with absolute ID (mixed type of anemia: AI + IDA) or functional ID (AI) in patients with sepsis or septic shock hospitalised in the ICU. Therefore, the aim of the study is to improve diagnosis of iron deficiency (ID) and anemia of inflammation (AI) with absolute ID (AI + IDA) or functional ID (AI) in patients with sepsis or septic shock.

ID have negative effects on the body and is associated with impaired production of proteins responsible for transport of oxygen in the blood (hemoglobin) and oxygen storage (myoglobin), and impaired immune function. Development of anemia is associated with well documented complications: organ hypoxia, myocardial infarction, stroke, infection. Replenishment of iron at this early stage may potentially prevent IDA. It is advantageous to replenish iron stores in order to avoid these complications, especially in patients with sepsis or septic shock. In IDA red blood cell transfusion is not recommended as it leads to other numerous complications. Therefore the patients presenting with laboratory results suggesting ID will receive divided doses od parenteral iron. Monitoring of iron replenishment will be based on a new laboratory parameter- reticulocyte hemoglobin equivalent.


Eligibility Criteria:
Inclusion Criteria:

* diagnosis of sepsis or septic shock according to the third international definition and appropriate diagnostic criteria

Exclusion Criteria:

* active bleeding
* erythrocyte mean corpuscular volume (MCV) above the reference range
* diagnosed thalassemia or suspicion of thalassemia based on Mentzer index \[9\]
* pregnancy
Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis

The goal is to evaluate the efficacy and safety of tofacitinib in treating refractory prurigo nodularis.The main questions it aims to answer are

1. whether tofacitinib is effective in treating prurigo nodularis in the longpterm.
2. whether tofacitinib is safe in prurigo nodularis patients in the longpterm.


Eligibility Criteria:
Inclusion criteria:

1. age ≥18 years old;
2. patients diagnosed with PN with a duration of more than 6 months;
3. presence of at least 10 pruritic nodules;
4. a Worst Itch-Numeric Rating Scale (WI-NRS) score ≥7 one week before study;
5. a history of more than 2 weeks of ineffective topical glucocorticoid treatment or antihistamine therapy;
6. signed informed consent and cooperated with the follow up and complied the study protocol.

Exclusion criteria:

1. current used of biologic, systemic glucocorticoid or immunosuppressive agents; past used of jak inhibitors;
2. were pregnant or lactating;
3. abnormal findings for patients' complete blood count, liver functions, and kidney function tests;
4. presence of any infection or inflammatory; presence of active tumors or an increased risk of tumor complications；
5. systemic comorbidities that could interfere with or complicate study assessments.
6. those experiencing atopic dermatitis within 6 months were excluded from this study.
Effect of Pranayama on Periodontal Health

The objective of the study was to evaluate the levels of Peroxisome proliferator-activated receptor gamma (PPAR-γ), Nuclear factor-kappa B (NF-kB) and the presence of red complex microorganisms (RCM) such as Treponema denticola (T.d), Porphyromonas gingivalis (P.g) and Tannerella forsythia (T.f) in the subgingival tissues of chronic periodontitis subjects before and after intervention with pranayama as an adjunct to scaling and root planing.

Sixty chronic periodontitis subjects were selected out of which 30 subjects (control group) were treated with scaling and root planing (SRP) and 30 subjects (pranayama group) also underwent SRP and pranayama for 3 months. Clinical parameters were recorded and the presence of PPAR-γ, NF-kB and RCM were assessed at baseline and after 3 months

Eligibility Criteria:
Inclusion Criteria:

* presence of at least 20 teeth
* Probing pocket depth ≥ 5 mm

Exclusion Criteria:

* aggressive periodontitis
* systemic disorders
* pregnant \& lactating females
* smokers \& alcoholics
* immunocompromised individuals
Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal Cancer

The purpose of this study is to compare the efficacy and toxicity of docetaxel-cisplatin neoadjuvant chemotherapy followed by concurrent radiotherapy with cetuximab or weekly cisplatin in locally advanced nasopharyngeal carcinoma.

Although concurrent chemoradiation is the standard treatment modality for locally advanced nasopharyngeal carcinoma (NPC), high incidences of distant metastases and severe treatment related toxicities have become an obstacle to be overcome. A phase Ⅱ study conducted by Hui et al. showed that neoadjuvant docetaxel-cisplatin (TP) chemotherapy followed by concurrent chemoradiotherapy was superior to the standard concomitant chemoradiation in terms of the 3-year OS without significantly exacerbating the acute toxicities. Moreover, Bonner et al. demonstrated that RT with concurrent Cetuximab significantly improved the 5-year OS and did not increase the treatment induced toxicities when compared with RT alone. Therefore, we initiated this study to compare the efficacy and toxicity of the two regimens, neoadjuvant chemotherapy followed by concurrent radiotherapy with cetuximab or weekly cisplatin for locally advanced NPC.

Eligibility Criteria:
Inclusion Criteria:

1. Histopathologically proven nasopharyngeal carcinoma (WHO type 2 or 3)
2. Stage Ⅲ-ⅣB disease (AJCC/UICC 2009)
3. ECOG performance status of 0-1
4. Life expectancy of more than 6 months
5. Signed written informed consent
6. Adequate organ function including the following:

   * Absolute neutrophil count (ANC) \>= 1.5 \* 109/l
   * Platelets count \>= 100 \* 109/l
   * Hemoglobin \>= 10 g/dl
   * AST and ALT \<= 2.5 times institutional upper limit of normal (ULN)
   * Total bilirubin \<= 1.5 times institutional ULN
   * Creatinine clearance \>= 50 ml/min
   * Serum creatine \<= 1 times ULN

Exclusion Criteria:

1. Evidence of distant metastasis
2. Prior chemotherapy or anti-cancer biologic therapy for any type of cancer, or prior radiotherapy to the head and neck region
3. Other previous or concomitant cancer, except for in situ cervical cancer and cutaneous basal cell carcinoma
4. Pregnant or breast-feeding females, or females and males of childbearing potential not taking adequate contraceptive measures
5. Presence of an uncontrolled concomitant illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
An App to Reduce Cannabis Use Among Emerging Adults

This study is being completed to pilot prevention methods to promote wellness and reduce risky behaviors, including the use of substances such as cannabis. This study will help researchers learn about ways of delivering this information that is both appealing and helpful to young adults who use mobile apps.


Eligibility Criteria:
Inclusion Criteria:

* Reside in the US
* Speak and read English
* Have a smartphone on which the app can be downloaded
* Screen positive for cannabis use 3 or more times each week over the past month
* Report motivation to change cannabis as 1 or higher (using scale of 0-10)
* Meet Study verification criteria (i.e., use of CAPTCHA, IP address checks)

Exclusion Criteria:

* Use of Medical Cannabis
* Failure to meet study verification criteria
The Effect of Cannabidiol in Learning and Memory of Adults

The main objectives of this study were to test if a singular dose of Cannabidiol (1) enhances the learning and memory of healthy human subjects, (2) test if Cannabidiol has negative effects on Retroactive and Proactive Interference during learning, (3) and test if demographic factors will influence CBD's modulation of human learning and memory.

Using a randomized, double-blind, placebo-controlled two-arm case-crossover trial, this study investigates the effect of 246 milligrams (mg) of Cannabidiol (CBD) on the learning and memory scores of human subjects, as well as the effect of Cannabidiol on Proactive and Retroactive Interference. This study also investigated the influence of demographic factors on CBD's modulation of human learning and memory.

This study was conducted at Colorado State University-Pueblo (CSU Pueblo) with volunteers recruited from CSU Pueblo and the local Pueblo community. Fifty-seven subjects were randomized in a double-blind manner to receive either CBD or placebo before completing two versions of learning and memory assessments. Each version of the learning and memory assessment included the Montreal Cognitive Assessment (MOCA), the Rey Auditory Verbal Learning Task-Revised (RAVLT-R), and the Logical Memory Subject of the Weschler Memory Scale. Several components of the RAVLT-R were evaluated including the Sum of Trials (Trials I-V) score, Proactive Interference Ratio (PI Ratio), and Retroactive Interference (RI Ratio).

Eligibility Criteria:
Inclusion Criteria:

* Were 18 years of age or older

Exclusion Criteria:

* Were pregnant or breast-feeding
* Had been diagnosed with mental illness
* Didn't speak English fluently
* Had severe hearing problems
* Had recreational or opioid drug contaminants in their urine
* Were involved in criminal activity
Neurofilament Light Protein in Peripheral Blood Used as a Biomarker for Neurotoxicity After Isolated Limb Perfusion.

A prospective feasibility trial initially including 10 patients to investigate if Neurofilament light protein can be detected in peripheral blood in patients undergoing Isolated Limb Perfusion with chemotherapeutic agents. This biomarker could act as predictive biomarker for neurotoxicity after isolated limb perfusion.

In isolated limb perfusion (ILP) neurotoxicity is a known side effect, this is in spite of the fact that a relatively mild hyperthermic temperature is used which should be well tolerated by the nerves and other normal tissues in the limbs. It seems probable that the neurotoxicity observed after ILP results from both a thermal enhancement of drug toxicity combined with a local effect of a high tourniquet pressure that is used to isolate the blood flow. Prevention of regional and systemic toxicity is essential for improving the outcome after the procedure. It is known that both higher doses of melphalan, higher temperatures and longer perfusion time correlates to a higher toxicity. The Wieberdink method is a grading system for the reaction of the normal tissues after ILP and the grading is used as a routine in ILP today. Neurofilament light protein (NfL) is released into the cerebrospinal fluid (CSF) during axonal damage and has been shown to be elevated in different forms of dementia. An NfL assay sensitive enough to measure NfL in blood was recently developed. Its concentration reflects axonal injury in both central and peripheral nervous system disorders.The primary aim of this study is to investigate the possibility to measure neurofilament as a biomarker for peripheral nerve toxicity after isolated limb perfusion.

Eligibility Criteria:
Inclusion Criteria:

1. Patient scheduled for treatment with isolated limb perfusion
2. Age over 18 years
3. Signed informed consent

Exclusion Criteria:

* None